数据显示，华夏基金旗下1只基金位居天智航十大流通股东。华夏中证机器人ETF（562500）三季度增 持162.84万股，持有股数872.38万股，占流通股的比例为1.93%。根据测算，今日浮盈赚取约854.93万 元。 华夏中证机器人ETF（562500）成立日期2021年12月17日，最新规模227.98亿。今年以来收益4.35%， 同类排名2512/5579；近一年收益38.85%，同类排名2007/4202；成立以来收益6.24%。 1月12日，天智航涨5.46%，截至发稿，报18.94元/股，成交997.02万元，换手率0.12%，总市值86.36亿 元。 资料显示，北京天智航医疗科技股份有限公司位于北京市海淀区建枫路(南延)中关村西三旗金隅科技园 8号院2号楼，成立日期2010年10月22日，上市日期2020年7月7日，公司主营业务涉及专注于骨科手术导 航定位机器人的研发、生产、销售和服务。主营业务收入构成为：骨科手术导航定位机器人58.31%， 配套设备及耗材23.86%，技术服务16.49%，其他(补充)1.31%，其他0.04%。 从天智航十大流通股东角度 截至发稿，华龙累计任职时间3年145 ...

截至发稿，李树建累计任职时间2年120天，现任基金资产总规模197.58亿元，任职期间最佳基金回报 114.87%， 任职期间最差基金回报-6.47%。 李栩累计任职时间3年42天，现任基金资产总规模265.38亿元，任职期间最佳基金回报139.24%， 任职 期间最差基金回报-5.57%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 资料显示，北京天智航医疗科技股份有限公司位于北京市海淀区建枫路(南延)中关村西三旗金隅科技园 8号院2号楼，成立日期2010年10月22日，上市日期2020年7月7日，公司主营业务涉及专注于骨科手术导 航定位机器人的研发、生产、销售和服务。主营业务收入构成为：骨科手术导航定位机器人58.31%， 配套设备及耗材23.86%，技术服务16.49%，其他(补充)1.31%，其他0.04%。 从天智航十大流通股东角度 数据显示，易方达基金旗下1只基金位居天智航十大流通股东。易方达国证机器人产业ETF（159530） 三季度新进十大流通股东，持 ...

Core Viewpoint - Tianzhihang's stock price has experienced a decline recently, despite a significant increase in its stock price year-to-date, indicating potential volatility in the market [1][2]. Company Overview - Tianzhihang Medical Technology Co., Ltd. specializes in the research, production, sales, and service of orthopedic surgical navigation robots, with a revenue composition of 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1]. - The company was established on October 22, 2010, and went public on July 7, 2020 [1]. Financial Performance - For the period from January to September 2025, Tianzhihang reported a revenue of 187 million yuan, representing a year-on-year growth of 103.51%. However, the net profit attributable to shareholders was -114 million yuan, a decrease of 49.73% compared to the previous year [2]. - The stock price has increased by 55.26% year-to-date, but has seen declines of 8.76% over the last five trading days, 12.22% over the last twenty days, and 22.18% over the last sixty days [1]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 12.31% to 17,300, with an average of 26,094 shares held per shareholder, a decrease of 10.96% [2]. - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on February 17, where it recorded a net purchase of 26.27 million yuan [1]. Market Position - Tianzhihang is categorized under the pharmaceutical and biological industry, specifically in medical devices, and is associated with concepts such as robotics, specialized innovation, and medical equipment [2].

Core Viewpoint - Tianzhihang's stock price has shown significant volatility, with a year-to-date increase of 73.77%, but recent declines in the short term indicate potential market fluctuations [2]. Group 1: Stock Performance - As of October 31, Tianzhihang's stock price rose by 2.06% to 17.36 CNY per share, with a trading volume of 25.985 million CNY and a turnover rate of 0.33%, resulting in a total market capitalization of 7.916 billion CNY [1]. - Year-to-date, Tianzhihang's stock has increased by 73.77%, but it has experienced a decline of 1.92% over the last five trading days, 1.31% over the last 20 days, and 2.03% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, Tianzhihang reported revenue of 187 million CNY, representing a year-on-year growth of 103.51%. However, the net profit attributable to shareholders was -114 million CNY, a decrease of 49.73% year-on-year [3]. - The company's main business revenue composition includes 58.31% from orthopedic surgical navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [2]. Group 3: Shareholder Information - As of September 30, 2025, Tianzhihang had 17,300 shareholders, an increase of 12.31% from the previous period, with an average of 26,094 circulating shares per shareholder, a decrease of 10.96% [3]. - Among the top ten circulating shareholders, the E Fund National Robot Industry ETF holds 10.7803 million shares, marking its entry as a new shareholder, while the Huaxia CSI Robot ETF increased its holdings by 1.6284 million shares to 8.7238 million shares [3].

Core Insights - Tianzhihang is a leading company in the orthopedic surgical robot field in China, established in 2010 and listed on the Shanghai Stock Exchange in 2020 [1] Financial Performance - For Q3 2025, Tianzhihang reported revenue of 187 million yuan, ranking 40th out of 42 in the industry, significantly lower than the top competitor Mindray Medical at 25.83 billion yuan [2] - The company's net profit was -125 million yuan, placing it last in the industry, with a stark contrast to Mindray Medical's 7.814 billion yuan [2] - The main business revenue composition includes orthopedic surgical navigation robots at 73.07 million yuan (58.31%), supporting equipment and consumables at 29.90 million yuan (23.86%), and technical services at 20.66 million yuan (16.49%) [2] Profitability and Debt Ratios - As of Q3 2025, Tianzhihang's debt-to-asset ratio was 27.29%, slightly above the industry average of 27.21% [3] - The gross profit margin was 70.72%, higher than the industry average of 48.67% [3] Executive Compensation - Chairman Zhang Songgen's salary decreased from 1.3433 million yuan in 2023 to 798,500 yuan in 2024, a reduction of 544,800 yuan [4] - General Manager Xu Jin's salary also decreased from 1.3323 million yuan in 2023 to 799,500 yuan in 2024, a reduction of 532,800 yuan [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders increased by 12.31% to 17,300 [5] - The average number of circulating A-shares held per shareholder decreased by 10.96% to 26,100 [5] - Notable shareholders include E Fund National Robot Industry ETF and Huaxia CSI Robot ETF, with significant holdings [5]

Core Points - Tianzhihang's stock price decreased by 2.06% on October 23, trading at 17.15 CNY per share with a market capitalization of 7.763 billion CNY [1] - The company has seen a year-to-date stock price increase of 71.67%, but has experienced a decline of 4.19% over the last five trading days and 5.87% over the last twenty days [2] - As of June 30, 2025, Tianzhihang reported a revenue of 125 million CNY, a year-on-year increase of 114.89%, but a net profit loss of 57.548 million CNY, a decrease of 23.80% year-on-year [3] Company Overview - Tianzhihang Medical Technology Co., Ltd. specializes in the research, production, sales, and service of orthopedic surgical navigation robots, with 58.31% of its revenue coming from this segment [2] - The company was established on October 22, 2010, and went public on July 7, 2020 [2] - The company is classified under the pharmaceutical and biological industry, specifically in medical devices, and is involved in several concept sectors including small-cap stocks, medical devices, and robotics [2] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.14% to 15,400, with an average of 29,308 circulating shares per shareholder, an increase of 8.48% [3] - The seventh largest circulating shareholder is the Huaxia CSI Robotics ETF, which holds 7.0953 million shares as a new shareholder [3]

Group 1 - The core viewpoint of the news is that Tianzhihang's stock has experienced fluctuations, with a year-to-date increase of 75.28% but a recent decline in the last five and twenty trading days [1] - As of October 22, Tianzhihang's stock price was 17.51 yuan per share, with a market capitalization of 7.926 billion yuan [1] - The company has seen a net inflow of main funds amounting to 682,100 yuan, with significant buying and selling activities recorded [1] Group 2 - Tianzhihang Medical Technology Co., Ltd. specializes in the research, production, sales, and service of orthopedic surgical navigation robots, with a revenue composition of 58.31% from these robots [2] - The company was established on October 22, 2010, and went public on July 7, 2020, operating within the medical device sector [2] - For the first half of 2025, Tianzhihang reported a revenue of 125 million yuan, reflecting a year-on-year growth of 114.89%, while the net profit attributable to shareholders was -57.5482 million yuan, a decrease of 23.80% [2]

Core Viewpoint - Tianzhihang's stock price has experienced fluctuations, with a year-to-date increase of 71.17%, but a recent decline in the last five trading days by 6.91% [1] Group 1: Stock Performance - As of October 15, Tianzhihang's stock price was 17.10 CNY per share, with a market capitalization of 7.741 billion CNY [1] - The stock has seen a trading volume of 11.2079 million CNY, with a turnover rate of 0.14% [1] - Year-to-date, the stock has risen by 71.17%, but has declined by 6.91% over the last five trading days and 3.82% over the last twenty days [1] Group 2: Financial Metrics - For the first half of 2025, Tianzhihang reported revenue of 125 million CNY, representing a year-on-year growth of 114.89% [2] - The company recorded a net profit attributable to shareholders of -57.5482 million CNY, a decrease of 23.80% year-on-year [2] Group 3: Business Overview - Tianzhihang specializes in the research, production, sales, and service of orthopedic surgical navigation robots, with main business revenue composition: 58.31% from navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [1] - The company is categorized under the pharmaceutical and biological industry, specifically in medical devices and equipment [2]

Core Viewpoint - Tianzhihang Medical Technology Co., Ltd. has shown significant stock performance and financial growth, particularly in the orthopedic surgical navigation robot sector, despite facing challenges in net profit. Group 1: Stock Performance - On September 16, Tianzhihang's stock rose by 2.10%, reaching 18.00 CNY per share, with a trading volume of 77.72 million CNY and a turnover rate of 0.97%, resulting in a total market capitalization of 8.148 billion CNY [1] - Year-to-date, Tianzhihang's stock price has increased by 80.18%, with a 1.24% rise over the last five trading days, an 8.49% decline over the last 20 days, and a 29.03% increase over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent appearance on February 17, where it recorded a net purchase of 26.27 million CNY [1] Group 2: Company Overview - Tianzhihang, established on October 22, 2010, and listed on July 7, 2020, focuses on the research, production, sales, and service of orthopedic surgical navigation robots [2] - The company's revenue composition includes 58.31% from orthopedic surgical navigation robots, 23.86% from supporting equipment and consumables, 16.49% from technical services, and 1.31% from other sources [2] - As of June 30, the number of shareholders decreased by 7.14% to 15,400, with an average of 29,308 circulating shares per person, an increase of 8.48% [2] Group 3: Financial Performance - For the first half of 2025, Tianzhihang reported revenue of 125 million CNY, a year-on-year increase of 114.89%, while the net profit attributable to shareholders was -57.55 million CNY, a decrease of 23.80% year-on-year [2] - As of June 30, 2025, the top ten circulating shareholders included Huaxia CSI Robot ETF, which holds 7.10 million shares as a new shareholder [2]

Core Viewpoint - Tianzhihang is a leading enterprise in the orthopedic surgical robot industry in China, focusing on the research, production, sales, and service of orthopedic surgical navigation robots [1] Company Overview - Tianzhihang Medical Technology Co., Ltd. specializes in orthopedic surgical navigation robots and related equipment, consumables, technical services, and surgical center engineering [1] - The company is recognized as one of the top 10 robotics companies in China and serves as a key research center for national and local medical robotics [1] Financial Performance - For Q1 2025, the company reported revenue of 58.58 million yuan, a year-on-year increase of 102.40% [1] - The net profit for the same period was -13.20 million yuan, reflecting a year-on-year decrease of 31.22% [1] - The gross profit margin stood at 75.12% [1] Shareholder Information - As of March 31, 2025, the number of shareholders reached 16,633, an increase of 1,520 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1] Market Valuation - The latest closing price for Tianzhihang was 12.48 yuan, down 2.73%, with a price-to-book ratio of 4.32 and a total market capitalization of 5.649 billion yuan [1][2]